Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic inflammatory condition affecting synovial tissue, leading to joint dysfunction and increased mortality.
• Tumor Necrosis Factor (TNF) inhibitors represent the first class of biologic disease-modifying antirheumatic drugs (DMARDs) developed for RA treatment.

Purpose of the Study:

• To review the molecular mechanisms of action for both biological and synthetic DMARDs used in rheumatoid arthritis treatment.
• To discuss the limitations and adverse effects associated with current RA therapies.
• To analyze emerging alternative treatment strategies for RA.

Main Methods:

• Literature review of established and novel DMARDs for rheumatoid arthritis.
• Analysis of molecular pathways targeted by biological agents (e.g., TNF, IL-1, IL-6 inhibitors, B-cell depletion, T-cell costimulation inhibition).
• Evaluation of synthetic DMARDs and their integration into RA treatment regimens.

Main Results:

• Biological DMARDs, including TNF inhibitors, IL-1, and IL-6 inhibitors, offer targeted approaches to RA management.
• Novel mechanisms like B-cell depletion and T-cell costimulation inhibition provide further therapeutic options.
• Synthetic DMARDs are increasingly incorporated, expanding treatment paradigms.

Conclusions:

• Understanding the molecular mechanisms of DMARDs is crucial for optimizing RA treatment.
• Established therapies have limitations and adverse effects that necessitate exploring alternative approaches.
• The evolving landscape of RA treatment includes a diverse range of biological and synthetic agents targeting specific inflammatory pathways.